Skip to main content

Table 1 The clinical characteristics of the 4 subgroups in TCGA LUAD, TCGA SKCM and TCGA HNSC

From: Immune and stromal scoring system associated with tumor microenvironment and prognosis: a gene-based multi-cancer analysis

Variable

TCGA LUAD

TCGA SKCM

TCGA HNSC

Subtypes

HH

HL

LH

LL

P

HH

HL

LH

LL

P

HH

HL

LH

LL

P

Gender (%)/Chi-squared test

    

0.35

    

0.14

    

0.0016**

 Male

41 (43.2)

66 (42.6)

75 (48.4)

51 (53.1)

 

47 (58.0)

53 (55.8)

66 (69.5)

55 (67.9)

 

76 (75.2)

102 (65.4)

131 (84.0)

70 (69.3)

 

 Female

54 (56.8)

89 (57.4)

80 (51.6)

45 (46.9)

 

34 (42.0)

42 (44.2)

29 (30.5)

26 (32.1)

 

25 (24.8)

54 (34.6)

25 (16.0)

31 (30.7)

 

Median age (IQR)/ANOVA

66.5 (57.7–72.2)

69.4 (62.7–75.0)

63.3 (56.2–71.6)

65.3 (60.5–72.0)

 < 0.0001****

56.7 (46.4–64.8)

56.3 (45.0–71.6)

56.1 (49.0–68.7)

60.0 (46.4–70.9)

0.71

60.77 (53.51–68.99)

61.11 (55.03–69.86)

60.85 (53.03–67.88)

61.72 (53.04–69.02)

0.72

Pathologic T (%)/Chi-squared test

    

0.16

    

0.068

    

0.018*

 T0–2

86 (90.5)

139 (90.8)

129 (83.8)

81 (84.4)

 

38 (58.5)

39 (52.0)

35 (45.5)

24 (36.4)

 

37 (41.1)

64 (48.5)

41 (30.0)

40 (43.0)

 

 T3–4

9 (9.5)

14 (9.2)

25 (16.2)

15 (15.6)

 

27 (41.5)

36 (48.0)

42 (54.5)

42 (63.6)

 

53 (58.9)

68 (51.5)

96 (70.0)

53 (57.0)

 

Pathologic N (%)/Chi-squared test

    

 < 0.0001****

    

0.3

    

0.42

 N0–1

81 (85.3)

139 (93.9)

115 (75.2)

83 (88.3)

 

50 (68.5)

66 (77.6)

59 (68.6)

55 (78.6)

 

40 (49.4)

71 (60.2)

77 (58.8)

51 (60.0)

 

 N2–3

14 (14.7)

9 (6.1)

38 (24.8)

11 (11.7)

 

23 (31.5)

19 (22.4)

27 (31.4)

15 (21.4)

 

41 (50.6)

47 (39.8)

54 (41.2)

34 (40.0)

 

Pathologic M (%)/Fisher's test

    

0.3

    

0.27

    

0.16

 M0

69 (94.5)

95 (96.0)

105 (92.1)

63 (88.7)

 

70 (93.3)

86 (96.6)

87 (94.6)

64 (88.9)

 

40 (100)

56 (100)

57 (100)

29 (96.7)

 

 M1

4 (5.5)

4 (4.0)

9 (7.9)

8 (11.3)

 

5 (6.7)

3 (3.4)

5 (5.4)

8 (11.1)

 

0

0

0

1 (3.3)

 

Pathologic stage (%)/Chi-squared test

    

 < 0.0001****

    

0.38

    

0.16

 Stage I

47 (49.5)

106 (69.3)

64 (41.3)

54 (56.3)

 

19 (25.7)

24 (28.9)

18 (19.8)

14 (19.4)

 

2 (2.2)

11 (8.5)

5 (3.7)

9 (9.9)

 

 Stage II

28 (29.5)

31 (20.3)

43 (27.7)

19 (19.8)

 

12 (16.2)

19 (22.9)

29 (31.9)

23 (31.9)

 

13 (14.6)

28 (21.7)

17 (12.6)

15 (16.5)

 

 Stage III

16 (16.8)

11 (7.2)

39 (25.2)

14 (14.6)

 

38 (51.4)

37 (44.6)

39 (42.9)

28 (38.9)

 

18 (20.2)

20 (15.5)

24 (17.8)

17 (18.7)

 

 Stage IV

4 (4.2)

5 (3.3)

9 (5.8)

9 (9.4)

 

5 (6.8)

3 (3.6)

5 (5.5)

7 (9.7)

 

56 (62.9)

70 (54.3)

89 (65.9)

50 (54.9)

 

Survival rate (%)/log-rank

    

 < 0.0001****

    

 < 0.0001****

    

0.39

 3-year OS

60.7

78.4

45.5

69.2

 

75

85.1

60.8

79.4

 

56.2

65.6

52.7

54.4

 

 5-year OS

41.2

55

30.2

40.1

 

65.1

78.4

43.2

63.3

 

46.2

50.3

47

47.4

 
  1. LUAD lung adenocarcinoma, SKCM skin cutaneous melanoma, HNSC head and neck squamous cell carcinoma, NS not significant
  2. * < 0.05; ** < 0.01; *** < 0.001; **** < 0.0001